The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

For decades, scientists have tried to stop cancer by disabling the mutated proteins that are found in tumors. But many cancers manage to overcome this and continue growing. Now, scientists think they ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $75 price target on Silence Therapeutics (SLN) shares following a recent ...

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million Series B financing to ...

Rising demand for precision medicine & groundbreaking innovations in RNA sequencing drive growth in oncology, drug discovery, & personalized therapies. Akash Anand SNS Insider Pvt. Ltd 415-230-0044 ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...